文章：

肿瘤PET成像研究进展

Advances in PET imaging of cancer

原文发布日期：2023-05-31

DOI: 10.1038/s41568-023-00576-4

类型: Review Article

开放获取: 否

英文摘要：

Molecular imaging has experienced enormous advancements in the areas of imaging technology, imaging probe and contrast development, and data quality, as well as machine learning-based data analysis. Positron emission tomography (PET) and its combination with computed tomography (CT) or magnetic resonance imaging (MRI) as a multimodality PET–CT or PET–MRI system offer a wealth of molecular, functional and morphological data with a single patient scan. Despite the recent technical advances and the availability of dozens of disease-specific contrast and imaging probes, only a few parameters, such as tumour size or the mean tracer uptake, are used for the evaluation of images in clinical practice. Multiparametric in vivo imaging data not only are highly quantitative but also can provide invaluable information about pathophysiology, receptor expression, metabolism, or morphological and functional features of tumours, such as pH, oxygenation or tissue density, as well as pharmacodynamic properties of drugs, to measure drug response with a contrast agent. It can further quantitatively map and spatially resolve the intertumoural and intratumoural heterogeneity, providing insights into tumour vulnerabilities for target-specific therapeutic interventions. Failure to exploit and integrate the full potential of such powerful imaging data may lead to a lost opportunity in which patients do not receive the best possible care. With the desire to implement personalized medicine in the cancer clinic, the full comprehensive diagnostic power of multiplexed imaging should be utilized.

摘要翻译： 

分子成像在成像技术、成像探针与造影剂研发、数据质量以及基于机器学习的数据分析领域取得了巨大进展。正电子发射断层成像（PET）及其与计算机断层扫描（CT）或磁共振成像（MRI）结合形成的多模态PET-CT或PET-MRI系统，通过单次患者扫描即可获取丰富的分子、功能与形态学数据。尽管近年来技术不断进步且已有数十种疾病特异性造影剂和成像探针问世，临床实践中用于影像评估的参数仍仅限于肿瘤尺寸或平均示踪剂摄取量等少数指标。多参数体内成像数据不仅具有高度定量性，更能提供关于病理生理学、受体表达、代谢、肿瘤形态与功能特征（如pH值、氧合状态或组织密度）以及药物药效学特性的宝贵信息，从而通过造影剂衡量药物反应。它还能进一步定量绘制并空间解析肿瘤间与肿瘤内异质性，为靶向特异性治疗干预揭示肿瘤脆弱点。若未能充分开发利用这类强大成像数据的潜力，可能导致患者错失获得最佳诊疗的机会。随着在肿瘤临床中实施个性化医疗的愿景日益强烈，我们应充分发挥多元成像全面综合的诊断效能。

原文链接：

Advances in PET imaging of cancer